GlaxoSmithKline, a research-based pharmaceutical and healthcare company, has reported profit attributable to the shareholders of £961m or 19.6 pence per share for the quarter ended 31 March 2013 compared to £1.31bn or 26.0 pence per share for the same quarter ended previous year.
Subscribe to our email newsletter
Quarterly turnover was £6.47bn, down from restated £6.64bn for the same period last year.
GSK delivered core EPS of 26.9pence and dividend of 18pence for the first quarter of 2013.
The company expects to deliver full-year earnings per share growth of 3-4% at constant exchange rates.